70956-04-6

Basic information

• Product Name: Ranitidine HCl
• CAS NO: 70956-04-6
• Molecular Weight: 0
• Mol File: 70956-04-6.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ranitidine HCl(CAS DataBase Reference)
• NIST Chemistry Reference: Ranitidine HCl(70956-04-6)
• EPA Substance Registry System: Ranitidine HCl(70956-04-6)

Safety Data

• Hazardous Substances Data: 70956-04-6(Hazardous Substances Data)

Usage

General Description

Ranitidine HCl, also known as ranitidine hydrochloride, is a medication commonly used to treat conditions such as heartburn, acid reflux, and peptic ulcers. It belongs to a class of drugs called H2 blockers, which work by reducing the production of stomach acid. Ranitidine HCl is typically taken orally in the form of tablets, and it can also be prescribed in an injectable form for more severe conditions. It has been widely used for decades and is generally considered safe and effective for the treatment of gastrointestinal disorders. However, in 2019, concerns were raised about potential contamination of ranitidine with a cancer-causing substance called N-nitrosodimethylamine (NDMA), leading to recalls and further investigation into its safety.

Upstream product

• 75-52-5 nitromethane 
• 91756-97-7 N-methyl-N'-(2-<(5-dimethylaminomethyl)-furan-2-ylmethylthio>-ethyl)-carbodiimide 
• 506-59-2 N,N-dimethylammonium chloride 
• 66357-07-1 N-methyl-N'-(2-<(5-dimethylaminomethyl)-furan-2-ylmethylthio>-ethyl)-urea 
• 7440-44-0 pyrographite 
• 123-91-1 1,4-dioxane 
• 15433-79-1 (5-dimethylaminomethyl-furan-2-yl)-methanol 
• 151-56-4 ethyleneimine 
• 61832-41-5 (E-)-N-methyl-1-(methylthio)-2-nitroethanamine 
• 66356-53-4 5-{[(2-aminoethyl)thio]methyl}-N,N-dimethyl-2-furfurylamine 
• 67-47-0 5-hydroxymethyl-2-furfuraldehyde 
• 1623-88-7 5-chloromethylfurfural 
• 1350914-20-3 5-[[(2-acetamidoethyl)thio]methyl]furfural 
• 79589-16-5 5-[[(2-acetamidoethyl)thio]methyl]-N,N-dimethyl-2-furanmethanamine 

Downstream Products

• 73851-70-4 Ranitidine S-oxide 

Relevant articles and documents

Ranitidine oral preparation for treating new indications of erosive esophagitis

The invention discloses a ranitidine and a preparation method thereof, as well as a ranitidine preparation, a compound preparation and a preparation method thereof. The ranitidine has a low impurity content, high stability, and the preparation method is simple; the ranitidine preparation and the compound preparation prepared therefrom have high bioavailability and safety. The ranitidine, the ranitidine preparation and the compound preparation provided by the invention can effectively treat and maintain the treatment of erosive esophagitis.

Novel synthesis method for high-stability ranitidine bismuth citrate

The invention discloses a novel synthesis method for high-stability ranitidine bismuth citrate. The method includes the steps of: 1) preparing a raw material solution; 2) performing a reaction to prepare ranitidine; 3) purifying the ranitidine; 4) performing a salt forming reaction; 5) discolorizing and sterilizing a product; and 6) producing a ranitidine bismuth citrate finish product. The novel synthesis method, through reasonable process design, can increase the quality and stability of ranitidine, thereby improving the pharmacologic property and stability of the ranitidine bismuth citrate. The novel synthesis method is low in raw material cost, has gentle process conditions, is good in controllability and yield, and is suitable for industrial production.

Synthesis of ranitidine (Zantac) from cellulose-derived 5-(chloromethyl)furfural

The biomass-derived platform chemical 5-(chloromethyl)furfural is converted into the blockbuster antiulcer drug ranitidine (Zantac) in four steps with an overall 68% isolated yield. The Royal Society of Chemistry.